Acute Myelogenous Leukemia (AML) Clinical Studies

1 - 2 of 2


This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.

AAML1921; Bosutinib for Chronic Myeloid Leukemia

This study involves taking a study drug called bosutinib. The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).